Infectious Diseases Research

Below are current clinical trials.

155 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. A Study to Evaluate the Performance of Chembio Diagnostics Systems, Inc. DPP® Zika IgM Assay System With Fingerstick Whole Blood (MVSS CBD002-18 PRO)

   Rochester, Minn.

   The purpose of this study is to support the use of fingerstick whole blood on the Chembio DPP® Zika IgM Assay System.

2. Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

   Scottsdale/Phoenix, Ariz.

   This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who have failed prior therapy with pegylated interferon and RBV. The primary study hypothesis is that in at least one of the study arms, the percentage of participants achieving sustained viral response 12 weeks after the end of all study treatment (SVR12) will be superior to 58%.

3. Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis

   Rochester, Minn.

   The DRCFI treatment will influence the time to first pulmonary exacerbation compared to placebo.

4. A Study of the Effectiveness of the Electronic Nose with C. difficile Infected Stool

   Rochester, Minn.

   The purpose of this study is to see how effective a new technology called the electronic nose is in identifying specific infection (C. difficile) from stool samples, by analyzing the gasses the stool gives off.

5. A Study of Blood Mononuclear Cells from HIV Patients and Control Subjects

   Rochester, Minn.

   The purpose of this study is to provide the lab with a source of human PBMCs and serum from normal and HIV-1-infected individuals. We wish to analyze cells from HIV-infected and non-HIV infected individuals for levels of various proteins and mRNAs that are relevant to HIV research.

6. Extent of Donor Site Morbidity after Scaphoid Repair Surgery Using the Medial Femoral Condyle

   Rochester, Minn.

   The purpose of the study is to determine the extent of donor site morbidity after harvesting the medial femoral condyle for scaphoid nonunion treatment. The outcomes being measured are: superficial infection, deep infection, pain (short term), pain (long term), knee function and quality of  scar.

7. Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

   Scottsdale/Phoenix, Ariz.

   The purpose of this open-label extension of CDI-001 (subsequently referred to as PRISM 3) is to evaluate the safety and efficacy in reducing recurrence of CDI in adults who had a recurrence within 8 weeks of receiving CP101 or placebo in PRISM 3. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be eligible to be enrolled in the extension study and administered CP101. Approximately 70 subjects will receive CP101. The treatment duration will be 1 day. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following receipt of CP101. The primary efficacy and safety endpoints will be evaluated at 8 weeks post treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI.

8. Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

   Rochester, Minn.

   This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B. Hospitalized subjects with influenza A or B that have either a low oxygen level or a high respiratory rate will be eligible for study participation. This study will enroll adults, children and pregnant women.

9. A Study of the Quantiferon CMV Blood Test to Predict the Risk of CMV Returning After Treatment of the Disease in Solid Organ Transplant Recipients

   Rochester, Minn.

   The purpose of this study is to determine if a special laboratory test performed on a blood sample collected from you (the organ recipient) can accurately predict the risk CMV infection occurring again in the future, after the current disease is cured.

10. A Study of the Prevalence of the Oropharyngeal Human Papillomavirus in Partners of Patients with Oropharyngeal Squamous Cell Carcinoma

    Rochester, Minn., Scottsdale/Phoenix, Ariz.

    We are doing this research study to find out if partners of subjects with oropharyngeal cancer are infected with human papillomavirus (HPV) in their mouth or throat. Human papillomavirus causes some types of oropharyngeal cancer. It is not known if sexual partners of patients are at higher risk of having oral or throat HPV infection. It is also unknown if certain sexual behaviors increase the risk of oral HPV infection